Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8C62

Crystal structure of cisplatin/B-DNA adduct

8C62 の概要
エントリーDOI10.2210/pdb8c62/pdb
関連するPDBエントリー8C63 8C64
分子名称DNA (5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'), PLATINUM (II) ION (3 entities in total)
機能のキーワードduplex, b-dna, cisplatin, anticancer agent, metallodrug, dna
由来する生物種synthetic construct
タンパク質・核酸の鎖数2
化学式量合計8107.10
構造登録者
Troisi, R.,Tito, G.,Ferraro, G.,Sica, F.,Merlino, A. (登録日: 2023-01-11, 公開日: 2024-01-31, 最終更新日: 2024-02-28)
主引用文献Troisi, R.,Tito, G.,Ferraro, G.,Sica, F.,Massai, L.,Geri, A.,Cirri, D.,Messori, L.,Merlino, A.
On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Dalton Trans, 53:3476-3483, 2024
Cited by
PubMed Abstract: The reaction of Pt-based anticancer agents with arsenic trioxide affords robust complexes known as arsenoplatins. The prototype of this family of anticancer compounds is arsenoplatin-1 (AP-1) that contains an As(OH) fragment linked to a Pt(II) moiety derived from cisplatin. Crystallographic and spectrometric studies of AP-1 binding to a B-DNA double helix dodecamer are presented here, in comparison with cisplatin and transplatin. Results reveal that AP-1, cisplatin and transplatin react differently with the DNA model system. Notably, in the AP-1/DNA systems, the Pt-As bond can break down with time and As-containing fragments can be released. These results have implications for the understanding of the mechanism of action of arsenoplatins.
PubMed: 38270175
DOI: 10.1039/d3dt04302a
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.31 Å)
構造検証レポート
Validation report summary of 8c62
検証レポート(詳細版)ダウンロードをダウンロード

239492

件を2025-07-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon